Nkarta Inc NKTX.OQ reported a quarterly adjusted loss of 39 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of seven analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -38 cents to -35 cents per share.
Reported revenue was zero; analysts expected zero.
Nkarta Inc's reported EPS for the quarter was a loss of 39 cents.
The company reported a quarterly loss of $28.34 million.
Nkarta Inc shares had fallen by 25.9% this quarter and lost 49.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 20.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Nkarta Inc is 15.50
This summary was machine generated from LSEG data November 8 at 05:13 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.36 | -0.39 | Missed |
Jun. 30 2024 | -0.45 | -0.34 | Beat |
Mar. 31 2024 | -0.56 | -0.58 | Missed |
Dec. 31 2023 | -0.59 | -0.57 | Beat |
Comments